{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:35:22Z","timestamp":1793288122684,"version":"4.5.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.pharmthera.2007.06.006","type":"journal-article","created":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T11:28:04Z","timestamp":1184758084000},"page":"266-286","source":"Crossref","is-referenced-by-count":294,"title":["The role of amyloid \u03b2 peptide 42 in Alzheimer's disease"],"prefix":"10.1016","volume":"116","author":[{"given":"Mark A.","family":"Findeis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2007.06.006_bib1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1083\/jcb.200404149","article-title":"Neuronal membrane cholesterol loss enhances amyloid peptide generation","volume":"167","author":"Abad-Rodriguez","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200519120-00002","article-title":"The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors","volume":"19","author":"Aisen","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib4","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15216540600644853","article-title":"Evidence against the overexpression of APP in Down syndrome","volume":"58","author":"Argellati","year":"2006","journal-title":"IUBMB Life"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0006-2952(99)00212-9","article-title":"Ginseng pharmacology: multiple constituents and multiple actions","volume":"58","author":"Attele","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib8","doi-asserted-by":"crossref","first-page":"43419","DOI":"10.1074\/jbc.M404937200","article-title":"Selected non-steroidal anti-inflammatory drugs and their derivatives target \u03b3-secretase at a novel site - evidence for an allosteric mechanism","volume":"279","author":"Beher","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2004.10.010","article-title":"The role of \u03b1-synuclein in neurodegenerative diseases","volume":"105","author":"Bennett","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib10","doi-asserted-by":"crossref","first-page":"13407","DOI":"10.1073\/pnas.95.23.13407","article-title":"Propagating structure of Alzheimer's beta-amyloid(10-35) is parallel beta-sheet with residues in exact register","volume":"95","author":"Benzinger","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib12","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1074\/jbc.271.8.4436","article-title":"Cholesterol modulates \u03b1-secretase cleavage of amyloid precursor protein","volume":"271","author":"Bodovitz","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/jsbi.2000.4241","article-title":"Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates","volume":"130","author":"Bohrmann","year":"2000","journal-title":"J Struct Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","article-title":"Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42\/1-40 ratio in vitro and in vivo","volume":"17","author":"Borchelt","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.neurobiolaging.2004.02.006","article-title":"Is the Abeta vaccine the answer?","volume":"25","author":"Bowen","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer's disease in the United States and the pubic health impact of delaying disease onset","volume":"88","author":"Brookmeyer","year":"1998","journal-title":"Am J Public Health"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib17","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1523\/JNEUROSCI.23-13-05645.2003","article-title":"Presenilin redistribution associated with aberrant cholesterol transport enhances \u03b2-amyloid production in vivo","volume":"23","author":"Burns","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib18","doi-asserted-by":"crossref","first-page":"51100","DOI":"10.1074\/jbc.M309561200","article-title":"Generation of the \u03b2-amyloid peptide and the amyloid precursor protein C-terminal fragment \u03b3 are potentiated by FE65L1","volume":"278","author":"Chang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1096\/fj.05-5530fje","article-title":"Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides","volume":"20","author":"Chen","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/nature04667","article-title":"TMP21 is a presenilin complex component that modulates \u03b3-secretase but not \u03b5-secretase activity","volume":"440","author":"Chen","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib21","doi-asserted-by":"crossref","first-page":"32046","DOI":"10.1074\/jbc.M201750200","article-title":"Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability","volume":"277","author":"Dahlgren","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib22","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1073\/pnas.93.7.2996","article-title":"Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein","volume":"93","author":"Davis","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib23","doi-asserted-by":"crossref","first-page":"20887","DOI":"10.1074\/jbc.270.36.20887","article-title":"Amyloid beta-protein aggregation nullifies its pathologic properties in cultured cerebrovascular smooth muscle cells","volume":"270","author":"Davis-Salinas","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/19083","article-title":"A presenilin-1-dependent \u03b3-secretase-like protease mediates release of Notch intracellular domain","volume":"398","author":"De Strooper","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib26","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.jnen.0000205145.54457.ea","article-title":"Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies","volume":"65","author":"Deramecourt","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib25","doi-asserted-by":"crossref","first-page":"37516","DOI":"10.1074\/jbc.M507913200","article-title":"RAC1 inhibition targets amyloid precursor protein processing by \u03b3-secretase and decreases A\u03b2 production in vitro and in vivo","volume":"280I","author":"D\u00e9sir\u00e9","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib28","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nbt0995-988","article-title":"A biotechnological method provides access to aggregation competent monomeric Alzheimer's 1-42 residue amyloid peptide","volume":"13","author":"Dobeli","year":"1995","journal-title":"Biotechnology (NY)"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib30","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.161102498","article-title":"Presenilin-dependent gamma-secretase activity modulates thymocyte development","volume":"98","author":"Doerfler","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2165\/00023210-200216120-00003","article-title":"Non-cholinergic strategies for treating and preventing Alzheimer's disease","volume":"16","author":"Doraiswamy","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","article-title":"Functional \u03b3-secretase inhibitors reduce \u03b2-amyloid peptide levels in brain","volume":"76","author":"Dovey","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib33","doi-asserted-by":"crossref","first-page":"20499","DOI":"10.1074\/jbc.274.29.20499","article-title":"Rank-order of potencies for inhibition of the secretion of A\u03b240 and A\u03b242 suggests that both are generated by a single \u03b3-secretase","volume":"274","author":"Durkin","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib34","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1042\/BST20051101","article-title":"Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention","volume":"33","author":"Eckman","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib35","unstructured":"Eckman, C. B., Yager, D., Haugabook, S., & Fauq, A. (2003) Methods of reducing \u03b2-amyloid polypeptides. United States Patent 6,649,196 B2. Nov. 18, 2003."},{"key":"10.1016\/j.pharmthera.2007.06.006_bib36","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.1134042","article-title":"Notch, a universal arbiter of cell fate decisions","volume":"314","author":"Ehebauer","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI200318162","article-title":"NSAID and enantiomers of flurbiprofen target \u03b3-secretase and lower A\u03b242 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/hmg\/ddi041","article-title":"Elevated amyloid \u03b2 protein (A\u03b242) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene","volume":"14","author":"Ertekin-Taner","year":"2005","journal-title":"Hum Mol Gen"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X","article-title":"Differences in the Abeta40\/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype","volume":"48","author":"Fagan","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib40","doi-asserted-by":"crossref","first-page":"24277","DOI":"10.1074\/jbc.M211992200","article-title":"Partial purification and characterization of \u03b3-secretase from post-mortem human brain","volume":"278","author":"Farmery","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib41","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/nbdi.2001.0447","article-title":"Presenilin-dependent gamma-secretase activity modulates neurite outgrowth","volume":"9","author":"Figueroa","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/1568026024607508","article-title":"Peptide inhibitors of beta amyloid aggregation","volume":"2","author":"Findeis","year":"2002","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib44","series-title":"Abstracts of Papers, 230th ACS National Meeting, Washington, DC, USA, Aug. 28-Sept. 1, 2005. Abstract #MEDI-233.","article-title":"Therapeutic approaches to Alzheimer's disease","author":"Findeis","year":"2005"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib45","unstructured":"Findeis, M. A., Pal, K., & Schroeder, F. (2006) Compounds useful for treating neurodegenerative disorders. PCT International Patent Application WO 2006\/124956 A1. 23 November 2006."},{"key":"10.1016\/j.pharmthera.2007.06.006_bib46","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1021\/bi0494976","article-title":"Purification and characterization of the human \u03b3-secretase complex","volume":"43","author":"Fraering","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib47","doi-asserted-by":"crossref","first-page":"41987","DOI":"10.1074\/jbc.M501368200","article-title":"\u03b3-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site","volume":"280","author":"Fraering","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib48","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1523\/JNEUROSCI.5170-04.2005","article-title":"Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model","volume":"25","author":"Fryer","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneur.60.7.958","article-title":"Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels","volume":"60","author":"Fukumoto","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000008156","article-title":"Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients","volume":"43","author":"Fukuyama","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1471-4159.2004.02154.x","article-title":"Modulation of \u03b2-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures","volume":"88","author":"Gasparini","year":"2004","journal-title":"J Neurochem"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2007.06.006_bib52","doi-asserted-by":"crossref","first-page":"14657","DOI":"10.1073\/pnas.0404866101","article-title":"Immunotherapy for Alzheimer's disease","volume":"101","author":"Gelinas","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 12","key":"10.1016\/j.pharmthera.2007.06.006_bib53","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20535","article-title":"How to diagnose dementia with Lewy bodies: state of the art","volume":"20","author":"Geser","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib55","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","article-title":"Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein","volume":"122","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jneumeth.2006.05.001","article-title":"A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain","volume":"157","author":"Goggi","year":"2006","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0925-4439(00)00043-0","article-title":"Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease","volume":"1502","author":"Golde","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib58","series-title":"Abstracts off the Alzheimer's Association International Conference on Prevention of Dementia, June 18-21, Washington, DC.","article-title":"Plasma A\u03b2 Levels as a Premorbid Biomarker for Cognitive Decline, Mild Cognitive Impairment (MCI) and Alzheimer Disease (AD)","author":"Graff-Radford","year":"2005"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib59","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1074\/jbc.270.13.7013","article-title":"Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immune","volume":"270","author":"Gravina","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib60","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1073\/pnas.94.6.2095","article-title":"The Alzheimer family of diseases: many etiologies, one pathogenesis?","volume":"94","author":"Hardy","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib61","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1074-5521(97)90303-3","article-title":"Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein","volume":"4","author":"Harper","year":"1997","journal-title":"Chem Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1096\/fj.00-0528fje","article-title":"Reduction of A\u03b2 accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin","volume":"15","author":"Haugabook","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0165-0270(01)00388-0","article-title":"High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid \u03b2 peptide (A\u03b2)","volume":"108","author":"Haugabook","year":"2001","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","article-title":"Alzheimer disease in the US population: prevalence estimates using the 2000 census","volume":"60","author":"Hebert","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib65","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib66","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.1237107100","article-title":"Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I\/glycogen synthase kinase-3beta","volume":"100","author":"Hoshi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, A\u03b2 elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib68","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1471-4159.2004.02581.x","article-title":"Apolipoprotein E modulates \u03b3-secretase cleavage of the amyloid precursor protein","volume":"90","author":"Irizarry","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(97)00347-9","article-title":"Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene","volume":"228","author":"Ishii","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2005.03.010","article-title":"Metabolism of amyloid-\u03b2 peptide and Alzheimer's disease","volume":"108","author":"Iwata","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib71","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.410370305","article-title":"Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome","volume":"37","author":"Iwatsubo","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib72","first-page":"1823","article-title":"Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques","volume":"149","author":"Iwatsubo","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/hmg\/ddh019","article-title":"Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase","volume":"13","author":"Jankowsky","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib74","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib75","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9","article-title":"Cerebrospinal fluid A\u03b242 is increased early in sporadic Alzheimer's disease and declines with disease progression","volume":"45","author":"Jensen","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neulet.2004.12.078","article-title":"Overexpression of calsenilin enhances gamma-secretase activity","volume":"378","author":"Jo","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib77","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1111\/j.1742-4658.2006.05263.x","article-title":"Physiochemical characterization of the Alzheimer's disease-related peptides A\u03b21-42Arctic and A\u03b21-42wt","volume":"273","author":"Johansson","year":"2006","journal-title":"FEBS J"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib78","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1083\/jcb.200410090","article-title":"A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation","volume":"167","author":"Kaether","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib79","unstructured":"Kane, A. (2007) Alzheimer's disease: beta-amyloid and beyond. Biotech Focus, APM HealthEurope, Number 4, January 5, 2007. www.apmhealtheurope.com. http:\/\/focus.apmhealtheurope.com\/freestory.php?bulletinsPage=1&bulletin=4"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib80","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precurson of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib81","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1523\/JNEUROSCI.5543-03.2004","article-title":"Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease","volume":"24","author":"Kawarabayashi","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib197","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1126\/science.1079469","article-title":"Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis","volume":"300","author":"Kayed","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib82","unstructured":"Kim, T. W., & Chung, S. (2005) Compounds for treating Alzheimer's disease and for inhibiting beta-amyloid peptide production. United States Patent Application Publication US 2005\/0245465 A1, Nov. 3, 2005."},{"key":"10.1016\/j.pharmthera.2007.06.006_bib83","unstructured":"Kim, N. D., Park, M. K., Lee, S. K., Park, J. H., Kim, & J. M. (1998) Processed ginseng product with enhanced pharmacological effects. United States Patent 5,776,460. July 7, 1998."},{"key":"10.1016\/j.pharmthera.2007.06.006_bib84","series-title":"Society for Neuroscience 35th Annual Meeting 2005, November 12-16, 2005. Washington, DC. Program number 817.2. A\u03b240 inhibits amyloid deposition and modulates premature death phenotype in vivo","author":"Kim","year":"2005"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1096\/fj.05-4055fje","article-title":"ERK1\/2 is an endogenous negative regulator of the gamma-secretase activity","volume":"20","author":"Kim","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/cb600135w","article-title":"A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide","volume":"1","author":"Kim","year":"2006","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib87","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.expneurol.2003.10.011","article-title":"Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?","volume":"185","author":"King","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0166-2236(00)01749-5","article-title":"Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?","volume":"24","author":"Klein","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib89","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.brainres.2004.10.041","article-title":"Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain","volume":"1031","author":"Kokubo","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib90","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1212\/WNL.48.3.741","article-title":"The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43)","volume":"48","author":"Kosaka","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib91","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9440(10)64947-4","article-title":"Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism","volume":"156","author":"Kuo","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.104.073965","article-title":"Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures","volume":"312","author":"Lanz","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib198","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneumeth.2006.03.023","article-title":"Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain","volume":"157","author":"Lanz","year":"2006","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib93","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000110372","article-title":"Smoking and Alzheimer's disease: a review of the epidemiological evidence","volume":"13","author":"Lee","year":"1994","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib94","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1073\/pnas.072033799","article-title":"A physiologic signaling role for the \u03b3-secretase-derived intracellular fragment of APP","volume":"99","author":"Leissring","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib95","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-beta protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib96","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1471-4159.2005.03553.x","article-title":"Inhibitors of Rho-kinase modulate amyloid-\u03b2 (A\u03b2) secretion but lack selectivity for A\u03b242","volume":"96","author":"Leuchtenberger","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib97","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI25410","article-title":"Anti-A\u03b242- and anti-A\u03b240-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model","volume":"116","author":"Levites","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","article-title":"Neurochemical diagnosis of Alzheimer's dementia by CSF A\u03b242, A\u03b242\/A\u03b240 ratio and total tau","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib99","doi-asserted-by":"crossref","first-page":"49523","DOI":"10.1074\/jbc.M402034200","article-title":"Tumor necrosis factor-\u03b1, interleukin-1 \u03b2, and interferon-\u03b3 stimulate \u03b3 -secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway","volume":"279","author":"Liao","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib100","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1073\/pnas.97.4.1456","article-title":"Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein","volume":"97","author":"Lin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib101","doi-asserted-by":"crossref","first-page":"47370","DOI":"10.1074\/jbc.M308480200","article-title":"Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression","volume":"278","author":"Lle\u00f3","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib102","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm1112","article-title":"Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation","volume":"10","author":"Lle\u00f3","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2007.06.006_bib103","doi-asserted-by":"crossref","DOI":"10.3310\/hta10010","article-title":"The clinical and cost effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease","volume":"10","author":"Loveman","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib104","doi-asserted-by":"crossref","first-page":"17342","DOI":"10.1073\/pnas.0506723102","article-title":"3D structure of Alzheimer's amyloid-beta(1-42) fibrils","volume":"102","author":"L\u00fchrs","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00024677-200504030-00006","article-title":"Black cohosh (Actaea\/Cimicifuga racemosa): review of the clinical data for safety and efficacy inmenopausal symptoms","volume":"4","author":"Mahady","year":"2005","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib106","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib107","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1042\/bst0300521","article-title":"Examining the structure of the mature amyloid fibril","volume":"30","author":"Makin","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib108","first-page":"1257","article-title":"Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene","volume":"148","author":"Mann","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib109","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/bbrc.1995.1280","article-title":"Secretion of Alzheimer beta\/A4 protein (1-40) and intracellular retention of beta\/A4 protein (1-42) in transfected COS cells","volume":"207","author":"Maruyama","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib110","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/BJ20050491","article-title":"Ubiquilin regulates presenilin endoproteolysis and modulates \u03b3-secretase components, Pen-2 and nicastrin","volume":"391","author":"Massey","year":"2005","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib111","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.61.1.7","article-title":"Setback for an Alzheimer's disease vaccine: lessons learned","volume":"61","author":"Mathews","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib113","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A\u03b240 and A\u03b242 and Alzheimer's disease: relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0197-4580(02)00157-4","article-title":"Is there a future for vaccination as a treatment for Alzheimer's disease?","volume":"24","author":"McGeer","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuron.2005.06.030","article-title":"A\u03b242 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice","volume":"47","author":"McGowan","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib116","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib117","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1074\/jbc.M906994199","article-title":"Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta-induced toxicity","volume":"275","author":"McLaurin","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/toxsci\/kfh254","article-title":"Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of gnes known to specify gut secretory lineage differentiation","volume":"82","author":"Milano","year":"2004","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib119","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1073\/pnas.1031520100","article-title":"Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo","volume":"100","author":"Miller","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib120","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ni1209","article-title":"Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21","volume":"6","author":"Minter","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib121","series-title":"10th International Conference on Alzheimer's Disease and Related Disorders, July 15-20, Madrid, Spain.","article-title":"Abstract P2-412. MPC-7869 (R-Flurbiprofen), a selective A\u03b242-lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease (AD): Analysis from a 12-month Phase 2 trial","author":"Mintzer","year":"2006"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib122","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.neurobiolaging.2004.02.005","article-title":"Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease","volume":"25","author":"Morgan","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib123","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib124","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/13506120208995241","article-title":"Intraneuronal Abeta42 accumulation in Down syndrome brain","volume":"9","author":"Mori","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib125","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","article-title":"High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation","volume":"20","author":"Mucke","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib126","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd1719","article-title":"Rho kinase, a promising drug target for neurological disorders","volume":"4","author":"Mueller","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib127","doi-asserted-by":"crossref","first-page":"12444","DOI":"10.1073\/pnas.1534745100","article-title":"Gleevec inhibits \u03b2-amyloid production but not Notch cleavage","volume":"100","author":"Netzer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1087-0024.2005.200404.x","article-title":"Notch and NOXA-related pathways in melanoma cells","volume":"10","author":"Nickoloff","year":"2005","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neuron.2005.04.008","article-title":"Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP","volume":"46","author":"Pardossi-Piquard","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib131","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1471-4159.2006.03822.x","article-title":"Neprilysin activity and expression are controlled by nicastrin","volume":"97","author":"Pardossi-Piquard","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2005.02.050","article-title":"Inhibition of angiogenesis and tumor growth by \u03b2 and \u03b3-secretase inhibitors","volume":"514","author":"Paris","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib133","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/archneur.58.12.2025","article-title":"Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline","volume":"58","author":"Parvathy","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib134","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1021\/jm0502541","article-title":"Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of \u03b2-amyloid1-42 secretion","volume":"48","author":"Peretto","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jnr.10747","article-title":"JLK isocoumarin inhibitors: selective \u03b3-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo","volume":"74","author":"Petit","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib136","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/bi051952q","article-title":"Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils","volume":"45","author":"Petkova","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib137","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1523\/JNEUROSCI.13-04-01676.1993","article-title":"Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state","volume":"13","author":"Pike","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib138","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1523\/JNEUROSCI.23-13-05531.2003","article-title":"The production of amyloid beta peptide is a critical requirement for the viability of central neurons","volume":"23","author":"Plant","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib139","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.neurobiolaging.2004.10.006","article-title":"Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases","volume":"26","author":"Pletnikova","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib140","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.1074\/jbc.270.16.9564","article-title":"Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture","volume":"270","author":"Podlisny","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib141","doi-asserted-by":"crossref","first-page":"50970","DOI":"10.1074\/jbc.M307699200","article-title":"Cyclooxygenase (COX)-2 and COX-1 potentiate \u03b2-amyloid peptide generation through mechanisms that involve \u03b3 secretase activity","volume":"278","author":"Qin","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib142","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1021\/bi049826u","article-title":"Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of \u03b3-secretase blockage","volume":"43","author":"Qyang","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib143","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1006\/nbdi.2001.0422","article-title":"A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease","volume":"8","author":"Refolo","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib144","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1046\/j.0014-2956.2001.02537.x","article-title":"NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox)","volume":"268","author":"Riek","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib145","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib146","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib147","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.neurobiolaging.2003.12.020","article-title":"Lessons from the AN 1792 Alzheimer vaccine: lest we forget","volume":"25","author":"Robinson","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib148","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jnr.1247","article-title":"Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42)","volume":"66","author":"Rockenstein","year":"2001","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib149","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ng1943","article-title":"The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease","volume":"39","author":"Rogaeva","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib150","doi-asserted-by":"crossref","first-page":"10836","DOI":"10.1073\/pnas.90.22.10836","article-title":"beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease","volume":"90","author":"Roher","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib151","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib152","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0896-6273(01)00475-5","article-title":"Clearing the brain's amyloid cobwebs","volume":"32","author":"Selkoe","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib199","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0076-6879(99)09047-3","article-title":"Toxicity of protein aggregates in PC12 cells: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay","volume":"309","author":"Shearman","year":"1999","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib200","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/bi0005456","article-title":"L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity","volume":"39","author":"Shearman","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib154","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-2001-3306","article-title":"Cerebrospinal fluid A\u03b240 and A\u03b242: natural course and clinical usefulness","volume":"3","author":"Shoji","year":"2001","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0197-4580(00)00229-3","article-title":"The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently","volume":"22","author":"Shoji","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib156","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer beta-amyloid by site-directed mAb","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib157","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1083\/jcb.152.4.785","article-title":"Presenilin 1 negatively regulates beta-catenin\/T cell factor\/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing","volume":"152","author":"Soriano","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib158","first-page":"26","article-title":"Getting to the root of ginseng","volume":"28","author":"Sticher","year":"1998","journal-title":"Chemtech"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib159","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01887400","article-title":"The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy","volume":"15","author":"Stine","year":"1996","journal-title":"J Protein Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib160","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.bmcl.2006.01.033","article-title":"The geminal dimethyl analogue of flurbiprofen as a novel A\u03b242 inhibitor and potential Alzheimer's disease modifying agent","volume":"16","author":"Stock","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib161","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.8191290","article-title":"An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants","volume":"264","author":"Suzuki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib162","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/bbrc.1994.2740","article-title":"Biochemical evidence for the long-tail form (A beta 1-42\/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease","volume":"205","author":"Tamaoka","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2004.12.131","article-title":"Widespread \u03b3-secretase activity in the cell, but do we need it at the mitochondria?","volume":"328","author":"Teng","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib164","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0306-4522(01)00095-1","article-title":"beta-Amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease","volume":"104","author":"Terai","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/mp.51.6.293","article-title":"Genetic risk factors in Alzheimer's disease","volume":"51","author":"Tilley","year":"1998","journal-title":"J Clin Pathol Mol Pathol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib166","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1073\/pnas.94.5.2025","article-title":"The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue","volume":"94","author":"Tomita","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib167","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Ueda","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib168","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0090-6980(98)00032-X","article-title":"Cationic lipids (lipofectamine) and disturbance of cellular cholesterol and sphingomyelin distribution modulates gamma-secretase activity within amyloid precursor protein in vitro","volume":"55","author":"Urmoneit","year":"1998","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib169","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1021\/bi034904j","article-title":"Gamma-secretase activity is present in rafts but is not cholesterol-dependent","volume":"42","author":"Wada","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/nbdi.2001.0470","article-title":"Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains","volume":"9","author":"Wahrle","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib171","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib172","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1042\/BST20051087","article-title":"The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention","volume":"33","author":"Walsh","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib173","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1523\/JNEUROSCI.4391-04.2005","article-title":"Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation","volume":"25","author":"Walsh","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib174","doi-asserted-by":"crossref","first-page":"31894","DOI":"10.1074\/jbc.271.50.31894","article-title":"The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry","volume":"271","author":"Wang","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib175","doi-asserted-by":"crossref","first-page":"40560","DOI":"10.1074\/jbc.M404345200","article-title":"Presenilins and \u03b3-secretase inhibitors affect intracellular trafficking and cell surface localization of the \u03b3-secretase complex components","volume":"279","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib176","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAID lower amyloidogenic A\u03b242 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib177","doi-asserted-by":"crossref","first-page":"30748","DOI":"10.1074\/jbc.M304824200","article-title":"A\u03b242-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain","volume":"278","author":"Weggen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib178","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1074\/jbc.M303592200","article-title":"Evidence That Nonsteroidal anti-inflammatory drugs decrease amyloid \u03b242 production by direct modulation of \u03b3-secretase activity","volume":"278","author":"Weggen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib179","series-title":"10th International Conference on Alzheimer's Disease and Related Disorders, July 15-20, Madrid, Spain.","article-title":"Abstract O4-03-08. Efficacy and safety of MPC-7869 (R-Flurbiprofen), a selective A\u03b242-lowering agent, in Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study","author":"Wilcock","year":"2006"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00001756-199801260-00008","article-title":"A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28\u00a0years","volume":"9","author":"Wisniewski","year":"1998","journal-title":"NeuroReport"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib181","doi-asserted-by":"crossref","first-page":"071","DOI":"10.1523\/JNEUROSCI.2381-04.2005","article-title":"Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death","volume":"25","author":"Wogulis","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib182","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/bst0300525","article-title":"Cholesterol and Alzheimer's disease","volume":"30","author":"Wolozin","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib183","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1021\/jm970621b","article-title":"A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity","volume":"41","author":"Wolfe","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib184","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","article-title":"Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related","volume":"82","author":"Wong","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib185","doi-asserted-by":"crossref","first-page":"12876","DOI":"10.1074\/jbc.M311652200","article-title":"Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation","volume":"279","author":"Wong","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib186","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1074\/jbc.272.12.7977","article-title":"Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins","volume":"272","author":"Xia","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib187","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12031-002-0023-5","article-title":"Natural Product Extracts that Reduce Accumulation of the Alzheimer's Amyloid \u03b2 Peptide: Selective Reduction in A\u03b242","volume":"19","author":"Yager","year":"2002","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib188","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0928-4257(98)80035-1","article-title":"The role of A beta 42 in Alzheimer's disease","volume":"92","author":"Younkin","year":"1998","journal-title":"J Physiol Paris"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib189","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1074\/jbc.274.13.8966","article-title":"Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production","volume":"274","author":"Zhang","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib190","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1021\/bi0028800","article-title":"Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides","volume":"40","author":"Zhang","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib191","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1083\/jcb.200110119","article-title":"Selective cytotoxicity of intracellular amyloid-\u03b2 peptide 1-42 through p53 and Bax in cultured primary human neurons","volume":"156","author":"Zhang","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib192","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/bi0481500","article-title":"Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin, aph-1a, and pen-2","volume":"44","author":"Zhang","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib193","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0092-8674(95)90073-X","article-title":"beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity","volume":"81","author":"Zheng","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib194","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1090154","article-title":"Nonsteroidal anti-inflammatory drugs can lower amyloidogenic A\u03b242 by inhibiting Rho","volume":"302","author":"Zhou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.06.006_bib195","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1073\/pnas.0502768102","article-title":"CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production","volume":"102","author":"Zhou","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2007.06.006_bib196","first-page":"27","article-title":"Molecular rationale for the pharmacological treatment of Alzheimer's disease","volume":"22","author":"Zimmermann","year":"2005","journal-title":"Drugs Aging"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372580700143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372580700143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T08:33:39Z","timestamp":1556699619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372580700143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":199,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S016372580700143X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2007.06.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}